Curtiss-Wright insider plans $1.67M stock sale

Curtiss-Wright executive K. Christopher Farkas filed a Rule 144 notice to sell 2,665 shares of common stock, with an aggregate market value of $1,669,034.61, through UBS Financial Services on or about February 4, 2026 on the NYSE.

Rhea-AI Filing Summary

Curtiss-Wright executive K. Christopher Farkas filed a Rule 144 notice to sell 2,665 shares of common stock, with an aggregate market value of $1,669,034.61, through UBS Financial Services on or about February 4, 2026 on the NYSE.

The 2,665 shares were acquired on February 3, 2026 via a performance stock vest from the issuer. Curtiss-Wright had 36,874,638 shares outstanding of this class. In the prior three months, Farkas sold 5,047 common shares on November 11, 2025 for gross proceeds of $2,916,463.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Curtiss-Wright (CW) Form 144 filing by K. Christopher Farkas disclose?

The filing discloses that K. Christopher Farkas plans to sell 2,665 Curtiss-Wright common shares, valued at $1,669,034.61, on the NYSE through UBS Financial Services. It also lists his prior three‑month sale of 5,047 shares for $2,916,463.

How many Curtiss-Wright (CW) shares is K. Christopher Farkas planning to sell under Rule 144?

He filed to sell 2,665 shares of Curtiss-Wright common stock. The notice shows an aggregate market value of $1,669,034.61 for this block, to be sold on or about February 4, 2026, on the NYSE via UBS Financial Services Inc.

How did K. Christopher Farkas acquire the Curtiss-Wright (CW) shares being sold?

The 2,665 Curtiss-Wright common shares were acquired on February 3, 2026, via a performance stock vest from the issuer. The filing lists the transaction as a performance-based equity vesting, with payment characterized as “n/a,” rather than a cash purchase.

What prior Curtiss-Wright (CW) stock sales by K. Christopher Farkas are reported in the Form 144?

The notice reports that Farkas sold 5,047 Curtiss-Wright common shares on November 11, 2025. Those shares generated gross proceeds of $2,916,463, and this transaction is included as required disclosure of sales during the preceding three months.

How many Curtiss-Wright (CW) shares were outstanding relative to this Form 144 sale?

Curtiss-Wright had 36,874,638 common shares outstanding, as stated in the filing. This figure provides context for the planned 2,665‑share sale under Rule 144, showing the sale size relative to the company’s total outstanding common stock.

Which broker and exchange are involved in the Curtiss-Wright (CW) Form 144 sale?

The planned sale will be executed through UBS Financial Services Inc., located in Weehawken, New Jersey. The Form 144 specifies that the 2,665 Curtiss-Wright common shares are expected to be sold on the New York Stock Exchange (NYSE).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:45 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001621241
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Curtiss-Wright Corporation
SEC File Number	001-00134
Address of Issuer	130 Harbour Place Drive, Suite 300 Davidson NORTH CAROLINA 28036
Phone	973-541-3753
Name of Person for Whose Account the Securities are To Be Sold	K. Christopher Farkas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	2665	1669034.61	36874638	02/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	02/03/2026	performance stock vest	issuer			2665	02/03/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
K. Christopher Farkas 130 Harbour Place Drive, Suite 300 Davidson NC 28036	common	11/11/2025	5047	2916463

144: Remarks and Signature

Remarks
Date of Notice	02/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Mijo Suric, for UBS Financial Services Inc, as attorney-in-fact for K. Christopher Farkas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)